Oncolytics Biotech® Inc.

This company aimed on the development of oncolytic viruses for use as cancer therapeutics in some of the most prevalent forms of the disease, covering lung, colorectal and pancreatic cancers. Nowadays, their lead product, REOLYSIN^®, is entering into late stage (Phase III) clinical testing. REOLYSIN^® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus and has been used alone and in combination with biologics, chemotherapy and radiotherapy for various cancers.